Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : KDUS, who knows this company? -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (113)	5/2/2000 12:36:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 117

Tuesday May 2, 12:03 pm Eastern Time Company Press Release Axiom Biotechnologies Receives Notice of Allowance on Two Patents for Cell-Based Compound Profiling SAN DIEGO--(BW HealthWire)--May 2, 2000--Axiom Biotechnologies Inc. today announced that it has received Notice of Allowance from the United States Patent and Trademark Office on two U.S. patent applications for instrumentation and methods relating to pharmacology profiling of compounds in cell-based assays. The two Allowed patent applications will expand the Company's patent portfolio by protecting the use of flow-based analytical systems for profiling compounds on living cells using a variety of cell-based approaches to assess receptor pharmacology, mechanism of action and toxicity endpoints. ``These two Allowances further reinforce Axiom's position as a leader in cell-based analyses for post-screening compound profiling,'' said Pandi Veerapandian, President & Chief Scientific Officer. ``We are particularly pleased to extend and protect our flow-based approaches beyond fluorimetry into flow cytometry where the company can perform high efficiency analyses of cultured cell populations, as well as patient cell samples for pharmacogenomic applications.'' The titles of the two patent applications are, ``Apparatus and Method for Compound Profiling of Living Cells,'' and ``Cell Flow Apparatus and Method for Real-Time Measurements of Cellular Response,'' and the Company expects these patents to issue later this year. Axiom Biotechnologies is a privately-held biotechnology company focused on improving the efficiency of drug discovery by accelerating the process of lead profiling by applying an array of proprietary ``hits-to-leads'' technologies and assays. The company's patented flagship technology, the High Throughput Pharmacology System (HT-PS), combines proprietary natural cell-based assays, high throughput automated instrumentation and novel pharmacoinformatics and biomining tools to assess and prioritize potential lead compounds based on their functional pharmacological properties. Through collaborations with pharmaceutical and biotechnology companies, Axiom is committed to becoming the pharmaceutical industry's partner of choice in high throughput pharmacology. Contact: Axiom Biotechnologies Stephen Eisold, Chief Executive Officer, 858/455-4500 www.axiombio.com